Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

NCT00488436 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00488436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00488436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2002
Completion date
December 31, 2007
Enrollment
25 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome